

Curriculum vitae



Name	Beekman, Jeffrey Matthijn, PhD
Date, Place of birth	June 13 1977, Nijmegen
Citizenship	Dutch
Address (home)	Cor Vlotlaan 6, 3526 XV, Utrecht
Address (work)	Wilhelmina Children's Hospital/University Medical Center Utrecht Huispost KH01.419.0 P.O. Box 85090 3508 AB Utrecht The Netherlands
Email	j.beekman@umcutrecht.nl
Mobile	+31 6 39 59 70 78

Biography and personal statement

Dr. J.M. Beekman obtained a PhD in molecular biology in 2004, and performed multiple post docs in molecular and cell biology within various immunological settings. In October 2010, he became principle investigator at the UMC Utrecht, and started a novel translational research line focusing on developing novel therapeutic and diagnostic strategies for cystic fibrosis, a genetic disease characterized by aberrant ion and fluid homeostasis at mucosal surfaces leading to chronic infection and inflammation and reduced lifespan.

'People with cystic fibrosis living healthy lives: I strive to create breakthrough solutions for clinical needs of people with chronic diseases by scientific research that focuses on the development of novel diagnostic or therapeutic approaches. This requires a multidisciplinary approach in which basic and clinical research is aligned, and integrated with needs of patients, the private sector and regulatory authorities. Currently, I am particularly proud of leading a team that developed a highly innovative diagnostic assay that enables individualized therapy for people with cystic fibrosis, leading to direct clinical impact for people within 4 years after the initial discovery.'

Academic fields

Cystic fibrosis, adult stem cells, CFTR-restoring drugs, inflammation, molecular cell biology, immunology

Education and Professional experience

<i>September 2013 – present:</i>	Associate Professor and Principal Investigator, Dept of Pediatric Pulmonology, UMCU
<i>October 2010 – August 2013:</i>	Assistant Professor and Principal Investigator, Dept of Pediatric Pulmonology, UMCU
<i>October 2005 – October 2010:</i>	Post-Doc, Dept of Immunology, UMCU
<i>October 2004 – Sept 2005:</i>	Post-Doc, Central Hematology Laboratory, RUN
<i>April 2000 – September 2004:</i>	Doctorate, Dept of Immunology, UMCU Promotor: Prof dr J.G.J van de Winkel Title of thesis: Biology of the high affinity IgG receptor FcγRI
<i>August 1995 – April 2000:</i>	Medical Biology, University of Utrecht, Awarded with Honours

Extracurricular activities

2016	Grant reviewer Canadian Foundation for Innovation
2016	Grant reviewer Cystic Fibrosis Research, Inc. (CFRI)
2016	Grant reviewer German CF society
2016	Advisor for future funding of UK Cystic Fibrosis Trust (Research Sandpit Workshop, 8-9 Feb)
2015	Grant reviewer SRC grant application Cystic Fibrosis Trust (UK)
2015	Organization and chair of preconference meeting for the ECFS 2016 Basic science meeting
2015	Avicenna Roadmap Authoring Team – A strategy for <i>in silico</i> clinical trials
2015	Organization and chair ‘Host pathogen interactions’ ECFS basic science meeting
2014	Organization and chair ‘Gene editing symposium’ NACFC 2014
2014	Organization and chair of preconference meeting: ‘human models for diagnosis, prognosis and response to therapy’ at ECFS Basic science meeting
2013 –	Editorial board member of Rare Diseases
2013 –	Editorial board member of PlosOne
2013 –	Candidate selection committee for Eureka Institute of Translational Medicine
2010 – 2012	Advisor of Technology Transfer Platform for Cystic Fibrosis of Stichting Carpe Diem, The Netherlands
2010 –	Reviewer for various journals including PlosOne, Journal of Immunological Methods, Journal of Leukocyte Biology, Molecular Immunology, Journal of Medical Genetics, Journal of Cystic Fibrosis

Memberships

2010 –	European Cystic Fibrosis Society
2011 –	Eureka Institute for Translational Medicine
2000 –	Dutch Society of Immunology (NIVI)

Teaching

2016	Faculty of Hands-on Workshop on Epithelial Systems: Physiology and Pathophysiology by European CF society and University of Lisbon
2015 – 2016	Faculty and guest lectures for Eureka institute for Translational Medicine, 7th Annual International Certificate Program; 2016 Summer school
2013 – 2016	Participation in courses for Research school Regenerative Medicine - Personalizing cystic fibrosis using intestinal organoids
2013 – 2016	Participation in courses for Selective Utrecht Medical Masters (SUMMA): - Pathophysiology Child health – Cystic Fibrosis, from bench to bed - Evaluator of OP1 and OP3 programs
2008 – 2013	Guest lectures in master courses of Eijkman Research school Infection and Immunology: - Immuno-gentherapy - Pathophysiology of the immune system - Signaling in the immune system - Top 10 techniques in immunology - Introduction Immunology I and III

Group members

Marne Hagemeyer, Post-doc

Gimano Amatngalim, Post-doc
Domenique van Ommen, Msc, PhD candidate
Gitte Berkers, MD, PhD candidate
Peter van Mourik, MD, PhD candidate
Eyleen de Poel, PhD candidate
Annelotte Vonk, Msc, Technician
Evelien Krusselbrink, Technician
Hugo Oppelaar, Technician

Alumni:

Florijn Dekkers, Msc, PhD candidate, PhD awarded cum laude
Pauline van de Weert-van Leeuwen, MD, PhD
Lodewijk Vijftigschild, Msc, PhD candidate, thesis defense 7 Dec 2016
Marit van Meegen, MD, PhD candidate, thesis defense 27 Sept 2016
Jennifer Speirs, MD
Rosa Smeets, laboratory assistant

Prizes (personal and group members)

European CF society (ECFS) – Gerd Doring award 2015
Dutch Respiratory Society (NRS) – Best translational research prize 2012-2014
Dutch Society for Pediatrics (NVK) – Best translational research article 2013

Presentation awards:

European CF society, Basic Science Meeting 2014, 2013, 2011
CF Young investigator meeting 2013

Poster awards:

North American CF conference 2014, poster finalist
Dutch CF Society research meeting 2011
European CF society, basic science meeting 2011

Invited Presentations (selection from 2014-2017)

International conferences

Keystone Symposium: Engineered Cells and Tissues as Platform for Discovery and Therapy, Mar, 2017
EMBL Symposium on Organoids, Oct, 2016
European Respiratory Society, September 2016
European Cystic Fibrosis Society annual conference, June, 2016
Dutch Respiratory Society, annual conference, Apr, 2016
European Respiratory Society, April, 2016: workshop on in new vitro models for airway disease
European Respiratory Society, Sept, 2015
NWO Bessensap, June, 2015
European Cystic Fibrosis Society annual conference, June, 2015
CFF research conference: pushing the frontiers. Panel discussion personalized therapy, June, 2015.
Dutch Respiratory Society (Longdagen 2015), April 2015
2nd Tissue Models & Phenotypic Screening Conference, May, 2015
Cell Based Assays, Phenotypic Screening and Pioneering Technologies, March, 2015
European Society for cell and gene therapy, October, 2014
North American CF conference, October 2014
European Cystic Fibrosis Society, June, 2014
3rd international meeting of German Lung Research center (DLZ), May 2014
Dutch Respiratory Society (Longdagen 2014), April 2014
European CF Basic Science Meeting, March, 2014

Cystic Fibrosis European Diagnostic Working group, February 2014

Invitations by academic collaborators

University Hospital Leuven – 2015; Prof Dr K de Boeck
University of Heidelberg – 2014; Prof Dr M. Mall
University of Hannover – 2013; Prof Dr B. Tuemmler
University of Iowa – 2012; Prof. Dr. J Zabner & Prof Dr M. Welsh,
McGill University – 2012; Prof Dr G. L. Lukacs
The Scripps Research Institute – 2012; Prof Dr W.E. Balch

Industries

Vertex, Stockholm – 2016 Education workshop on intestinal organoids and CFTR modulators
Vertex, Chimay – 2016 1st Basic science meeting of Belgium and Luxembourg
Pfizer, Boston – 2013; Dr M. Pregel
Novartis, Horsham – 2012; Dr M. Verkuil

Regulatory authorities

EMA, London – 2015, Dec 8: Gastrointestinal (GI) outcome measures to evaluate CFTR modulators for the treatment of cystic fibrosis. Title: The role of intestinal organoid function for evaluation of CFTR modulators

Patient information meetings

Dutch CF foundation, patient meetings, November 2012, 2013, 2014, 2015
CF Parent's night, Erasmus MC, April 2014
Publiekslezing Cystic Fibrosis UMCU, April, 2013

Currently active grants

2017 – 2019 ZonMW/NCFS/GLPGS/TKI 40-41200-98-9296: *New drugs and combinations thereof for the treatment of cystic fibrosis: a better understanding and application using patient derived cell systems*

Role: Project leader, €480K

Goal: Study mode of action of new GLPG correctors

2017 – 2019 NCFS/Haga Apotheek/TKI: Understanding of dose-effect relationships of CFTR modulators in individual patients with Cystic Fibrosis to realise a personalised dosing regimen per patient.

Role: Project leader, co-applicant with Prof Dr CK van der Ent. Total amount: €230K

Goal: Develop novel technology for individual PK assessment of CFTR modulator ivacaftor

2016 – 2017 Investigator initiated study from Vertex Pharmaceuticals: *Pilot study into the efficacy of VX809 in combination with VX 770 in patients with an A455E-CFTR mutation.*

Role: project leader. Co-applicant with Prof Dr CK van der Ent.

2015 – 2018 ZonMW TOP 40-00812-98-14103: *Cure for a genetic disease? Targeting the right drug to the right patient using intestinal stem cell cultures in Cystic Fibrosis.*

Role: project leader, secretary. Co-applicant with Prof Dr CK van der Ent, Prof Dr I Braakman, Dr H. de Jonge. Total amount: €675,000. Beekman €300,000

Goal: To develop a predictive model for individual therapy using intestinal organoids and define mechanisms of optimal compound combinations for CFTR repair.

2015 – 2017 European H2020 program (SEP-210176765): *Clinical proof of concept for a RNA-targeting Oligonucleotide for a Cystic Fibrosis-F508del medication.*

Role: Workpackage leader biomarkers. Co-applicants: ProQR therapeutics, ECFS, UCL, INSERM, Patergrus.

Total amount € 5,999,000; Beekman €230,000.

Goal: perform biomarker analysis for a first in human trial for novel RNA oligo based RNA editing technology

2014 – 2016 ZonMW 40-41200-98-9216 *Personalizing B2-adrenergic receptor agonist therapy for people with CF using in vitro cultures of intestinal organoids.*

Role: project leader. Co-applicants: Prof dr CK van der Ent, Dr HGM Heijerman, Dr H de Jonge, Dr I Bronsveld.

Total amount €299,856. Beekman €200,000

Goal: demonstrate proof-of-concept for using organoids as screening platform to repurpose existing drugs for select CF subsets

2014 – 2016 ZonMW 40-41200-98-9227 *CFTR repair by genistein, curcumin and VX-770 (Ivacaftor) in cystic fibrosis patients carrying the S1251N channel gating mutation.*

Role: co-applicant. Project leader Dr HR de Jonge, co-applicants: Prof Dr CK van der Ent, Dr HGM Heijerman, Dr I Bronsveld, Dr AG Vulto.

Total amount €299,492, Beekman €100,000

Goal: demonstrate proof-of-concept for using organoids as screening platform to repurpose food components as potentiators for CF S1251N subsets

Previous Grants

2013-2014 NCFs COS: *Personalized therapy of CF: comparison of in vitro methods for prediction of individual drug efficacy.*

Role: project leader.

Total amount €50.000.

Goal: comparison of individual measurements by electrophysiology or fluid secretion in organoids derived from those biopsies

2012-2013 NCFs COS+: Development of a human intestinal culture model for personalized treatment of cystic fibrosis.

Role: project leader.

Total amount €50.000.

Goal: set up of functional CFTR assay in human organoids

2011-2013 Dutch Scientific Organisation (NWO): Mosaic grant of Msc. J.J. Speirs: Immune dysfunction in cystic fibrosis: unravelling the mechanisms of disease for novel insights and therapeutic opportunities (NWO 017.008.141).

Role: project supervisor.

Total amount €200,000 for Msc J.J. Speirs

Goal: define CFTR-dependent mechanisms that contribute to increased allergic responses by fungal stimuli.

2011-2012 Infection and Immunity Center Utrecht: Seeding grant. *Lipid membrane alteration of the phagosomal membrane allows bacterial survival in Cystic Fibrosis monocytes.*

Role: co-applicant with Prof. dr. J.B. Helms.

Total amount €55.000

Goal: analyze lipid composition of intracellular vesicles from CF and non CF monocytes

2010-2012 Wilhelmina Research Fund: *Improving CF diagnosis and treatment by studying CFTR activity in patient-derived primary cells using a novel fluorescent sensor.*

Role: project leader. Co-applicants: Prof Dr CK van der Ent, Dr SHW Terheggen.

Total amount for Beekman € 103,114.

Goal: development of novel fluorescent sensors for analysis of CFTR function and drug responses

2008-2010 Wilhelmina Research Fund. *Analysis of CFTR function in the immune system: towards novel therapeutics to control lung pathology.*

Role: post doc. Co-applicants: Prof Dr CK van der Ent, Dr SHW Terheggen.

€120,438

Goal: CFTR analysis (protein and function) in immune cells from peripheral blood

Patent-applications (inventor)

Diagnosing a disease or affliction that affects fluid uptake or secretion or for studying the effectiveness of one or more drugs for treating the disease or affliction comprises measuring swelling of organoids

Patent Number(s): WO2013093812-A2 ; WO2013093812-A3

Inventor(s): BEEKMAN J M, DEKKERS J F, VAN DER ENT C K, CLEVERS J C

Patent Assignee Name(s) and Code(s): UMC UTRECHT HOLDING BV (UMCU-Non-standard)

Derwent Primary Accession Number: 2013-L45333 [61]

Publications

Five key publications

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis

Johanna F. Dekkers, Gitte Berkers, Evelien Kruisselbrink, Annelotte Vonk, Hugo R. de Jonge, Hettie M. Janssens, Inez Bronsveld, Eduard A. van de Graaf, Edward E. S. Nieuwenhuis, Roderick H. J. Houwen, Frank P. Vleggaar, Johanna C. Escher, Yolanda B. de Rijke, Christof J. Majoer, Harry G. M. Heijerman, Karin M. de Winter-de Groot, Hans Clevers, Cornelis K. van der Ent and [Jeffrey M. Beekman](#) (June 22, 2016).

Science Translational Medicine 8 (344), 344ra84. [doi: 10.1126/scitranslmed.aad8278]

Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients.

Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N, Boymans S, Cuppen E, van der Ent CK, Nieuwenhuis EE, [Beekman JM](#), Clevers H.

Cell Stem Cell. 2013 Dec 5;13(6):653-8.

A functional CFTR assay using primary cystic fibrosis intestinal organoids

J.F. Dekkers, C.L. Wiegerinck, H.R. de Jonge, I. Bronsveld, H.M. Janssens, K.M. de Winter-de Groot, A.M. Brandsma, N.W.M. de Jong, M.J.C. Bijvelds, B.J. Scholte, E.E.S. Nieuwenhuis, S. van den Brink, H. Clevers, C.K. van der Ent, S. Middendorp, [J.M. Beekman](#).

Nat Med. 2013 Jul;19(7):939-45

Mechanism-based corrector combination synergistically restores $\Delta F508$ - CFTR folding and function in cystic fibrosis

Tsukasa Okiyoneda, Guido Veit, Johanna F. Dekkers, Haijin Xu, Ariel Roldan, Miklos Bagdany, A. S. Verkman, Mark Kurth, Agnes Simon, Tamas Hegedus, [Jeffrey M. Beekman](#), Gergely L. Lukacs.

Nat Chem Biol. 2013 Jul;9(7):444-54

Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids

Johanna F. Dekkers, Ricardo A. Gogorza Gondra, Evelien Kruisselbrink, Annelotte M. Vonk, Hettie M. Janssens, Karin M. de Winter-de Groot, Cornelis K. van der Ent, [Jeffrey M. Beekman](#)

European Respiratory Journal 2016 Apr 21. doi: 10.1183/13993003.01192-2015.

Other peer reviewed journals

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients

Eric WFW. Alton, [Jeffrey M. Beekman](#), A. Christopher Boyd, June Brand, Mary M. Connolly, *et al.* Thorax. 2017 Feb;72(2):137-147.

Individualized medicine using intestinal responses to CFTR potentiators and correctors.

Beekman JM.
Pediatr Pulmonol. 2016 Oct;51(S44):S23-S34.

Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration.

Noordhoek J, Gulmans V, van der Ent K, Beekman JM.
Curr Opin Pulm Med. 2016 Nov;22(6):610-6.

β2-adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with CF.

L.A. Vijftigschild, J.F. Dekkers, E. Matthes, E. Kruisselbrink, A.M. Vonk, K.M. de Winter - de Groot, I. Bronsveld, H.M. Janssens, J.W. Hanrahan, C.K. van der Ent, J.M. Beekman
European Respiratory Journal, 2016, in press

Functional Characterization of Cholera Toxin Inhibitors Using Human Intestinal Organoids.

Zomer-van Ommen DD, Pukin AV, Fu O, Quarles van Ufford LH, Janssens HM, [Beekman JM](#), Pieters RJ.
J Med Chem. 2016 Jul 7

Potentiator synergy in rectal organoids carrying S1251N, G551D or F508del CFTR mutations

Johanna F. Dekkers, Peter Van Mourik, Annelotte M. Vonk, Evelien Kruisselbrink, Gitte Berkers, Karin M. de Winter - de Groot, Hettie M. Janssens, Inez Bronsveld, Cornelis K. van der Ent, Hugo R. de Jonge and [Jeffrey M. Beekman](#)
J Cyst Fibros. 2016 May 5. pii: S1569-1993(16)30024-8. doi: 10.1016/j.jcf.2016.04.007.

Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids

Johanna F. Dekkers, Ricardo A. Gogorza Gondra, Evelien Kruisselbrink, Annelotte M. Vonk, Hettie M. Janssens, Karin M. de Winter-de Groot, Cornelis K. van der Ent, [Jeffrey M. Beekman](#)
European Respiratory Journal 2016 Apr 21. doi: 10.1183/13993003.01192-2015.

rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and CF Mice.

Vidović D, Carlon MS, F da Cunha M, Dekkers JF, Hollenhorst MI, Bijvelds MJ, Ramalho AS, Van den Haute C, Ferrante M, Baekelandt V, Janssens HM, De Boeck K, Sermet-Gaudelus I, de Jonge HR, Gijsbers R, [Beekman JM](#), Edelman A, Debyser Z.
Am J Respir Crit Care Med. 2016 Feb 1;193(3):288-98.

Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25-28 March 2015.

Verkman AS, Edelman A, Amaral M, Mall MA, [Beekman JM](#), Meiners T, Galiotta LJ, Bear CE.
J Cyst Fibros. 2015 Nov;14(6):700-5. doi: 10.1016/j.jcf.2015.10.001.

Modeling rotavirus infection and antiviral therapy using primary intestinal organoids.

Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, Tuysuz N, Dekkers JF, Wang Y, de Jonge J, Sprengers D, van der Laan LJ, [Beekman JM](#), Ten Berge D, Metselaar HJ, de Jonge H, Koopmans MP, Peppelenbosch MP, Pan Q.
Antiviral Res. 2015 Nov;123:120-31. doi: 10.1016/j.antiviral.2015.09.010.

An inducible mouse model for microvillus inclusion disease reveals a role for myosin Vb in apical and basolateral trafficking.

Schneeberger K, Vogel GF, Teunissen H, van Ommen DD, Begthel H, El Bouazzaoui L, van Vugt AH, [Beekman JM](#), Klumperman J, Müller T, Janecke A, Gerner P, Huber LA, Hess MW, Clevers H, van Es JH, Nieuwenhuis EE, Middendorp S.

Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12408-13. doi: 10.1073/pnas.1516672112.

Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.

Zomer-van Ommen DD, Vijftigschild LA, Krusselbrink E, Vonk AM, Dekkers JF, Janssens HM, de Winter-de Groot KM, van der Ent CK, [Beekman JM](#).

J Cyst Fibros. 2015 Aug 5. pii: S1569-1993(15)00169-1. doi: 10.1016/j.jcf.2015.07.007.

A bioassay using intestinal organoids to measure CFTR modulators in human plasma.

Dekkers R, Vijftigschild LA, Vonk AM, Krusselbrink E, de Winter-de Groot KM, Janssens HM, van der Ent CK, [Beekman JM](#).

J Cyst Fibros. 2015 Mar;14(2):178-81.

Modulation of the maladaptive stress response to manage diseases of protein folding.

Roth DM, Hutt DM, Tong J, Bouche-careilh M, Wang N, Seeley T, Dekkers JF, [Beekman JM](#), Garza D, Drew L, Masliah E, Morimoto RI, Balch WE.

PLoS Biol. 2014 Nov 18;12(11):e1001998.

CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014.

[Beekman JM](#), Sermet-Gaudelus I, de Boeck K, Gonska T, Derichs N, Mall MA, Mehta A, Martin U, Drumm M, Amaral MD.

J Cyst Fibros. 2014 Jul;13(4):363-72

VX-809 and Related Corrector Compounds Exhibit Secondary Activity Stabilizing Active F508del-CFTR after Its Partial Rescue to the Cell Surface.

Eckford PD, Ramjeesingh M, Molinski S, Pasyk S, Dekkers JF, Li C, Ahmadi S, Ip W, Chung TE, Du K, Yeger H, [Beekman JM](#), Gonska T, Bear CE.

Chem Biol. 2014 May 22;21(5):666-78.

Chronic inflammation and infection associate with a lower exercise training response in cystic fibrosis adolescents.

van de Weert-van Leeuwen PB, Hulzebos HJ, Werkman MS, Michel S, Vijftigschild LA, van Meegen MA, van der Ent CK, [Beekman JM](#), Arets HG.

Respir Med. 2014 Mar;108(3):445-52.

Effect of long-term voluntary exercise wheel running on susceptibility to bacterial pulmonary infections in a mouse model.

van de Weert-van Leeuwen PB, de Vrankrijker AM, Fentz J, Ciofu O, Wojtaszewski JF, Arets HG, Hulzebos HJ, van der Ent CK, [Beekman JM](#), Johansen HK.

PLoS One. 2013 Dec 23;8(12):e82869.

Novel opportunities for CFTR-targeting drug development using organoids

Dekkers JF, van der Ent CK, [Beekman JM](#).

Rare Diseases 2013; 1:e27112; <http://dx.doi.org/10.4161/rdis.27112>

Optimal Complement-Mediated Phagocytosis of Pseudomonas aeruginosa by Monocytes is CFTR-Dependent.

van de Weert-van Leeuwen PB, van Meegen MA, Speirs JJ, Pals DJ, Rooijackers SH, Van der Ent CK, Terheggen-Lagro SW, Arets HG, [Beekman JM](#).

Am J Respir Cell Mol Biol. 2013 Apr 25.

Cell-penetrating bisubstrate-based protein kinase C inhibitors

Liskamp, Rob; Van Wandelen, Loek; Van Ameijde, Jeroen; Ismail-Ali, Ahmed; Quarles van Ufford, Linda; Vijftigschild, Lodewijk; [Beekman, Jeffrey M](#); Martin, Nathaniel; Ruijtenbeek, Rob.

ACS Chem Biol. 2013 May 8

Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis

M.A. van Meegen, S.W.J. Terheggen-Lagro, K.J. Koymans, C.K. van der Ent, J.M. Beekman.
Plos One, 2013;8(3):e57617.

CFTR-mutation specific applications of CFTR-directed monoclonal antibodies

M.A. van Meegen, S.W.J. Terheggen, K.J. Koymans, L.A.W. Vijftigschild, J.F. Dekkers, C.K. van der Ent, J.M. Beekman.
J Cyst Fibros. 2013 Jan 11.

A Novel Fluorescent Sensor for Measurement of CFTR Function by Flow Cytometry

Lodewijk Vijftigschild, Cornelis K van der Ent, Jeffrey M Beekman.

Cytometry part A, 2013 Mar 5

Infection, inflammation and exercise in cystic fibrosis

Pauline Barbera van de Weert-van Leeuwen, Hubertus Gerardus Maria Arets, Cornelis Korstiaan van der Ent, Jeffrey Matthijn Beekman.

Respiratory Research, 2013 Mar 6;14:32

A concise preparation of the fluorescent amino acid L-(7-hydroxycoumarin-4-yl) ethylglycine and extension of its utility in solid phase peptide synthesis.

Koopmans T, van Haren M, van Ufford LQ, Beekman JM, Martin NI.

Bioorg Med Chem. 2013 Jan 15;21(2):553-9.

Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen presenting cells.

Haveman LM, Bierings M, Klein MR, Beekman JM, de Jager W, Kuis W, Albani S, Prakken BJ.

Clin Immunol. 2013 Jan 16;146(3):228-239.

Effects of Aspergillus fumigatus colonization on lung function in cystic fibrosis

JJ Speirs, CK van der Ent, JM Beekman.

Curr Opin Pulm Med, 2012, Sept 6

PPARgamma as a therapeutic target in cystic fibrosis

J.F. Dekkers, C.K. van der Ent, E. Kalkhoven, J.M. Beekman.

Trends Mol Med. 2012 May;18(5):283-91.

STAT3 regulates monocyte TNF-alpha production in systemic inflammation caused by cardiac surgery with cardiopulmonary bypass.

de Jong PR, Schadenberg AW, van den Broek T, Beekman JM, van Wijk F, Coffey PJ, Prakken BJ, Jansen NJ.

PLoS One. 2012;7(4):e35070.

CFTR Expression Analysis in Human Nasal Epithelial Cells by Flow Cytometry. M.A. van Meegen, S.W.H.

Terheggen-Lagro, C.K. van der Ent, J.M. Beekman.

PLoS One. 2011;6(12):e27658.

Syntenin-mediated regulation of Sox4 proteasomal degradation modulates transcriptional output

J.M. Beekman, S.J. Vervoort, J.F. Dekkers, M.E. van Vesseem, S. Vendelbosch, A. Brugulat-Panès, J. van Loosdregt, K. Braat, P.J. Coffey.

Oncogene. 2011 Oct 10:1-12

Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization.

J. van Loosdregt, Y. Vercoulen, T. Guichelaar, Y.Y. Gent, J.M. Beekman, O. van Beekum, A.B. Brenkman, D.J. Hijnen, T. Mutis, E. Kalkhoven, B.J. Prakken, P.J. Coffey.

Blood. 2010 Feb 4;115(5):965-74.

Regulation of myelopoiesis through syntenin-mediated modulation of IL-5 receptor output.

J.M. Beekman, L.P. Verhagen, N. Geijsen, P.J. Coffe.
Blood. 2009 Oct 29;114(18):3917-27.

Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

W. de Jager, S.J. Vastert, J.M. Beekman, N.M. Wulffraat, W. Kuis, P.J. Coffe, B.J. Prakken.
Arthritis Rheum. 2009 Sep;60(9):2782-93.

Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells.

Y. Vercoulen, E.J. Wehrens, N.H. van Teijlingen, W. de Jager, J.M. Beekman, B.J. Prakken.
PLoS One. 2009 Sep 25;4(9):e7183.

The ins-and-outs of syntenin: a multifunctional intracellular adapter protein

J.M. Beekman, P.J. Coffe.
J Cell Sci. 2008 May 1;121(Pt 9):1349-55.

HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation.

L.M. Kuijk, J.M. Beekman, J. Koster, H.R. Waterham, J. Frenkel, P.J. Coffe.
Blood. 2008 Nov 1;112(9):3563-73.

FcgammaRI (CD64) resides constitutively in lipid rafts

J.M. Beekman, J.A. van der Linden, J.G.J. van de Winkel, J.H.W. Leusen.
Immunol Lett. 2008 Mar 15;116(2):149-55.

Protein 4.1G binds to a unique motif within the FcgammaRI cytoplasmic tail

J.M. Beekman, J.E. Bakema, J.A. van der Linden, B.B.J. Tops, J.G.J. van de Winkel, J.H.W. Leusen.
Mol Immunol. 2008 Apr;45(7):2069-75

Filamin A stabilizes FcgammaRI surface expression and prevents its lysosomal routing

J.M. Beekman, C.E. van der Poel, J.A. van der Linden, D.L.C. van den Berg, P.V.E. van den Berghe, J.M. Griffith, M.J. Kleijmeer, J.G.J. van de Winkel, J.H.W. Leusen.
J Immunol. 2008 Mar 15;180(6):3938-45.

A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

B. de Rijke, A. van Horssen-Zoetbrood, J.M. Beekman, B. Otterud, F. Maas, R. Woestenenk, M. Kester, M. Leppert, A.V. Schattenberg, T. de Witte, E. van de Wiel-van Kemenade, H. Dolstra.
J Clin Invest. 2005 Dec;115(12):3506-1

Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin.

J.M. Beekman, J.A. van der Linden, J.E. Bakema, B. Tops, M. Hinten, M. van Vugt, J.G.J. van de Winkel, J.H.W. Leusen.
J Biol Chem. 2004 Aug 6;279(32):33875-81

Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity.

J.M. Beekman, J.E. Bakema, J.G.J. van de Winkel, and J.H.W. Leusen.
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10392-7

